Wednesday, October 28, 2026

Back to today

From X

Danaher’s robotics era

Danaher’s new CEO paired a Q3 beat and raised EPS outlook with a 2027 4%-5% organic-growth starting point, while pitching AI-enabled…

BSX · long

Boston Scientific CORP

Boston Scientific, the interventional cardiac-device leader, is rated long after a share-price and P/E decline tied to slower market growth…

Sixty Dollars or Nothing

Chiron granted seven executives 195,610 options at a $60 strike, 63% above the market price and above its published valuation range.

Trading Post 9/4/2026

Lululemon reported a 9% global comparable-sales decline, 20% lower leggings sales and mid-single-digit operating-margin guidance, with…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.